To evaluate the efficacy of ixekizumab combined with tirzepatide in achieving skin clearance and weight loss in patients with moderate-to-severe plaque psoriasis and obesity.
Key Findings:
27% of patients receiving ixekizumab plus tirzepatide achieved both complete skin clearance and at least 10% weight loss at 36 weeks.
6% of patients receiving ixekizumab alone achieved the same outcomes.
41% of patients in the combination arm achieved Psoriasis Area and Severity Index 100 compared to 29% in the monotherapy arm.
Interpretation:
The combination therapy demonstrated superior efficacy in achieving both skin clearance and weight loss compared to ixekizumab monotherapy in patients with psoriasis and obesity.
Limitations:
The study population had a high mean BMI (>39 kg/m²) and significant disease burden, which may limit generalizability.
Adverse events were reported, though they were generally mild to moderate.
Conclusion:
Concomitant treatment with ixekizumab and tirzepatide is a promising approach for managing psoriasis in patients with obesity, showing significant improvements in skin clearance and weight loss.
